The primary finding of our study showed a significant reduction in the primary outcome of AF recurrence risk among diabetic patients taking SGLT2 inhibitors (SGLT2i) compared to those not on non‐SGLT2i drugs, highlighting the potential benefit of SGLT2i. Here, SLC5A2 is linked to atrial fibrillation.